JP2017528468A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017528468A5 JP2017528468A5 JP2017513506A JP2017513506A JP2017528468A5 JP 2017528468 A5 JP2017528468 A5 JP 2017528468A5 JP 2017513506 A JP2017513506 A JP 2017513506A JP 2017513506 A JP2017513506 A JP 2017513506A JP 2017528468 A5 JP2017528468 A5 JP 2017528468A5
- Authority
- JP
- Japan
- Prior art keywords
- trastuzumab
- population
- antibody
- relative frequency
- galactose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229960000575 trastuzumab Drugs 0.000 claims 15
- 238000000034 method Methods 0.000 claims 10
- 229930182830 galactose Natural products 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 229950006780 n-acetylglucosamine Drugs 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 108010021468 Fc gamma receptor IIA Proteins 0.000 claims 1
- 102000030902 Galactosyltransferase Human genes 0.000 claims 1
- 108060003306 Galactosyltransferase Proteins 0.000 claims 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims 1
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 1
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000033581 fucosylation Effects 0.000 claims 1
- 150000004676 glycans Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14184201 | 2014-09-10 | ||
| EP14184201.3 | 2014-09-10 | ||
| US201462095912P | 2014-12-23 | 2014-12-23 | |
| US62/095,912 | 2014-12-23 | ||
| PCT/EP2015/070285 WO2016037947A1 (en) | 2014-09-10 | 2015-09-04 | Galactoengineered immunoglobulin 1 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020156251A Division JP2021006540A (ja) | 2014-09-10 | 2020-09-17 | ガラクトース操作型免疫グロブリン１抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017528468A JP2017528468A (ja) | 2017-09-28 |
| JP2017528468A5 true JP2017528468A5 (enExample) | 2018-09-27 |
Family
ID=51518624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017513506A Withdrawn JP2017528468A (ja) | 2014-09-10 | 2015-09-04 | ガラクトース操作型免疫グロブリン１抗体 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20170253661A1 (enExample) |
| EP (2) | EP3191527B1 (enExample) |
| JP (1) | JP2017528468A (enExample) |
| CN (2) | CN114181312A (enExample) |
| WO (1) | WO2016037947A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6850351B2 (ja) | 2016-12-21 | 2021-03-31 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗体のインビトロ糖鎖工学 |
| EP3559250A1 (en) | 2016-12-21 | 2019-10-30 | H. Hoffnabb-La Roche Ag | Re-use of enzymes in in vitro glycoengineering of antibodies |
| AU2017381657B2 (en) * | 2016-12-21 | 2020-07-23 | F. Hoffmann-La Roche Ag | Method for in vitro glycoengineering of antibodies |
| US20220033511A1 (en) * | 2018-09-11 | 2022-02-03 | Amgen Inc. | Methods of modulating antibody-dependent cell-mediated cytotoxicity |
| EP4041773A1 (en) * | 2019-10-11 | 2022-08-17 | Beth Israel Deaconess Medical Center, Inc. | Anti-tn antibodies and uses thereof |
| US11975066B2 (en) | 2020-08-31 | 2024-05-07 | SAB Biotherapeutics, Inc. | Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof |
| EP4119672A1 (en) * | 2021-07-14 | 2023-01-18 | Sartorius Stedim Cellca GmbH | Method of modulating the extent of galactosylation of proteins in mammalian producer cells |
| CN114167060B (zh) * | 2021-11-25 | 2022-08-05 | 辽宁师范大学 | 一种肝癌生物标志物及检测肝癌的试剂盒 |
| US20250320279A1 (en) * | 2021-11-30 | 2025-10-16 | Sab, Llc | Ungulate-derived polyclonal immunoglobulin specific for influenza virus and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| MX9800684A (es) | 1995-07-27 | 1998-04-30 | Genentech Inc | Formulacion de proteinas liofilizadas isotonicas estables. |
| GB9603256D0 (en) * | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ATE321066T1 (de) | 1998-05-06 | 2006-04-15 | Genentech Inc | Anti-her2 antikörperzusammensetzung |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| FR2861080B1 (fr) * | 2003-10-20 | 2006-02-17 | Lab Francais Du Fractionnement | Anticorps presentant un taux de fucose et de galactose optimise |
| ME01775B (me) * | 2003-11-05 | 2011-02-28 | Glycart Biotechnology Ag | Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| WO2007005786A2 (en) * | 2005-06-30 | 2007-01-11 | Centocor, Inc. | Methods and compositions with enhanced therapeutic activity |
| CN101646775B (zh) * | 2006-12-28 | 2016-08-24 | 森托科尔奥索生物科技公司 | 用于产生脱唾液酸化免疫球蛋白的方法和载体 |
| US10087236B2 (en) * | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| WO2011149999A2 (en) * | 2010-05-27 | 2011-12-01 | Merck Sharp & Dohme Corp. | Method for preparing antibodies having improved properties |
| WO2012020065A1 (en) * | 2010-08-10 | 2012-02-16 | Glycotope Gmbh | Fab-glycosylated antibodies |
| BR112014003110A2 (pt) * | 2011-08-10 | 2018-10-09 | Lab Francais Du Fractionnement | composição, método para produção de uma população altamente galactosilada de anticorpos, células epiteliais de glândula mamária e mamífero não humano tramsgênico |
| US9365881B2 (en) * | 2011-10-05 | 2016-06-14 | Hoffmann-La Roche Inc. | Process for antibody G1 glycoform production |
| AR094781A1 (es) * | 2013-02-13 | 2015-08-26 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Anticuerpos anti-her2 (receptor 2 del factor de crecimiento epidérmico humano) altamente galactosilados y sus usos |
-
2015
- 2015-09-04 CN CN202111538475.2A patent/CN114181312A/zh active Pending
- 2015-09-04 JP JP2017513506A patent/JP2017528468A/ja not_active Withdrawn
- 2015-09-04 CN CN201580048480.1A patent/CN106687481B/zh not_active Expired - Fee Related
- 2015-09-04 EP EP15759788.1A patent/EP3191527B1/en active Active
- 2015-09-04 WO PCT/EP2015/070285 patent/WO2016037947A1/en not_active Ceased
- 2015-09-04 EP EP19175629.5A patent/EP3567056A1/en not_active Withdrawn
-
2017
- 2017-03-10 US US15/455,535 patent/US20170253661A1/en not_active Abandoned
-
2020
- 2020-06-25 US US16/911,712 patent/US20200325245A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017528468A5 (enExample) | ||
| JP2014531205A5 (enExample) | ||
| WO2013082519A3 (en) | Nucleotide-specific recognition sequences for designer tal effectors | |
| CN101679934B (zh) | 具有经修饰的岩藻糖基化的糖蛋白的生产 | |
| WO2020127417A3 (en) | PRODUCTION OF 3-FUCOSYLLACTOSE AND LACTOSE CONVERTING α-1,3-FUCOSYLTRANSFERASE ENZYMES | |
| CA2922888C (en) | Cells producing fc containing molecules having altered glycosylation patterns and methods and use thereof | |
| JP2014508759A5 (enExample) | ||
| EP4276179A3 (en) | Alpha-amylase variants | |
| JP2014525395A5 (enExample) | ||
| JP2016508515A5 (enExample) | ||
| WO2014118360A3 (en) | Carbohydrate degrading polypeptide and uses thereof | |
| WO2011091078A3 (en) | Antibody fc variants with enhanced complement activity | |
| US20150176045A1 (en) | Method for in Vivo Production of Deglycosylated Recombinant Proteins Used as Substrate for Downstream Protein Glycoremodeling | |
| WO2017011773A3 (en) | Codon-optimized nucleic acids encoding antibodies | |
| WO2013013013A3 (en) | Compositions and methods for producing modified glycoproteins | |
| WO2010132659A3 (en) | Anti-human cd52 immunoglobulins | |
| WO2011123830A3 (en) | Alpha 1-antitrypsin compositions and methods of making and using same | |
| WO2004074497A3 (en) | Endomannosidases in the modification of glycoproteins in eukaryotes | |
| WO2010033279A3 (en) | Antibodies with altered binding to fcrn and methods of using same | |
| WO2010129304A3 (en) | Method for making heteromultimeric molecules | |
| EA201071108A1 (ru) | Способ и система обеспечения контроля за изготовлением изделий | |
| HK1248714A1 (zh) | Ras蛋白的突变的片段 | |
| MX2013002657A (es) | Proceso para la produccion de fibrinogeno. | |
| NZ742745A (en) | Variants of chymosin with improved milk-clotting properties | |
| JP2020501577A5 (enExample) |